BrainsWay Ltd. (BWAY)

NASDAQ: BWAY · Real-Time Price · USD
12.73
+0.54 (4.43%)
At close: Aug 13, 2025, 4:00 PM
12.70
-0.03 (-0.24%)
After-hours: Aug 13, 2025, 4:10 PM EDT
4.43%
Market Cap 247.97M
Revenue (ttm) 43.46M
Net Income (ttm) 3.92M
Shares Out 36.90M
EPS (ttm) 0.08
PE Ratio 63.31
Forward PE 41.01
Dividend n/a
Ex-Dividend Date n/a
Volume 190,509
Open 12.99
Previous Close 12.19
Day's Range 12.70 - 12.99
52-Week Range 6.86 - 13.66
Beta 0.33
Analysts Strong Buy
Price Target 14.25 (+11.94%)
Earnings Date Aug 13, 2025

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 17, 2019
Employees 120
Stock Exchange NASDAQ
Ticker Symbol BWAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 11.94% from the latest price.

Price Target
$14.25
(11.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call ...

2 hours ago - Seeking Alpha

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2...

9 hours ago - GlobeNewsWire

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were a...

2 months ago - GlobeNewsWire

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

2 months ago - GlobeNewsWire

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar ...

2 months ago - GlobeNewsWire

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors LLC Hadar Levy – Chief Executive Officer Ido Marom – Chief ...

3 months ago - Seeking Alpha

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Achieved r ecord quarterly s ales of $11. 5 million in Q 1 202 5 , an increase of 27% compared to Q 1 202 4

3 months ago - GlobeNewsWire

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer ...

5 months ago - Seeking Alpha

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023

5 months ago - GlobeNewsWire

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...

8 months ago - GlobeNewsWire

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

9 months ago - GlobeNewsWire

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call P...

9 months ago - Seeking Alpha

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLI...

9 months ago - GlobeNewsWire

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

10 months ago - GlobeNewsWire

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...

11 months ago - GlobeNewsWire

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™

11 months ago - GlobeNewsWire

BrainsWay Announces Significant Expansion on U.S. East Coast

BURLINGTON, Mass. and JERUSALEM, Sept.

11 months ago - GlobeNewsWire

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...

1 year ago - GlobeNewsWire

BrainsWay Appoints Richard A. Bermudes, M.D.

Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field

1 year ago - GlobeNewsWire

BrainsWay: Operating Leverage Driving Upside

BrainsWay reported strong earnings in Q2, with growth remaining strong and margins continuing to improve. Growth among enterprise accounts and internationally should ensure BrainsWay continues to perf...

1 year ago - Seeking Alpha

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ:BWAY) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Part...

1 year ago - Seeking Alpha

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Generated Robust 28 % Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Four...

1 year ago - GlobeNewsWire

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

1 year ago - GlobeNewsWire

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

1 year ago - GlobeNewsWire

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™

1 year ago - GlobeNewsWire